home / stock / cue / cue news

CUE News and Press, Cue Biopharma Inc. From 08/22/22

Stock Information
Company Name: Cue Biopharma Inc.
Stock Symbol: CUE
Market: NASDAQ
Website: cuebiopharma.com
Menu
CUE CUE Quote CUE Short CUE News CUE Articles CUE Message Board
Get CUE Alerts

News, Short Squeeze, Breakout and More Instantly...
CUE - Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms' Tumor 1 (WT1) - expressing cancers

BOSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today t...
CUE - Catalyst watch: Jackson Hole, Nvidia earnings, Nogin SPAC deal and Rite Aid event

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

CUE - Cue Biopharma GAAP EPS of -$0.37

Cue Biopharma press release ( NASDAQ: CUE ): Q2 GAAP EPS of -$0.37. Cash and cash equivalents of $66.13M For further details see: Cue Biopharma GAAP EPS of -$0.37

CUE - Cue Biopharma Reports Second Quarter 2022 Financial Results

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported today se...
CUE - Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today t...

CUE - Cue Biopharma to Present at the JMP Securities Life Sciences Conference

BOSTON, June 13, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it...

CUE - Cue Biopharma to Present at the Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it...
CUE - Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it ...

CUE - Elevation Oncology, Cue Biopharma top healthcare gainers, Verrica, PMV lead losers' pack

Gainers: Elevation Oncology (ELEV) +20%. Cue Biopharma (CUE) +14%. Evelo Biosciences (EVLO) +13%. GeoVax Labs (GOVX) +13%. Immix Biopharma (IMMX) +9%. Losers: Verrica Pharmaceuticals (VRCA) -58%. PMV Pharmaceuticals (PMVP) -10%. TransMedics (TMDX) ...

CUE - Cue Biopharma: A First Assessment

Shares of Cue Biopharma have tumbled some 75% since November 2021, as somewhat underwhelming data from slowly developing Phase 1 trials are at fault. The company’s Immuno-STAT platform is a novel approach to immuno-oncology that should reduce risks associated with systemic expo...
Previous 10 Next 10